A form is the physical state in which a formulation reaches the reader — capsule, powder, liposomal delivery, chewable, tablet, liquid. It is not a matter of preference. It is not chosen for novelty, for fashion, or for distinction in the field. The form is determined by the ingredients within the composition, by how those ingredients behave in different physical states, by what the reader will encounter when taking the formulation, and by what the manufacturing process can sustain reliably.

Where The Blends speaks to composition — what ingredients belong together and why — The Forms speaks to the physical state in which a composition reaches the reader. The two are dimensions of the same formulation work, considered side by side. The composition asks: what is in this formulation? The form asks: in what state does this formulation arrive?

Three principles govern the work. The ingredients determine the form — what a compound tolerates, what it resists, what it requires in order to reach the reader stably, sets the boundary of which forms are available to it. The reader's encounter shapes the form — who will take the formulation, in what setting, with what ease, is part of the formulation's design. The manufacturing reality bounds the form — a form that cannot be produced reliably at standard does not enter the work.

These principles descend from The Standard and are observed in the discipline of The Restraint. The vocabulary that informs the conversation is collected in The Longevity Glossary.

Two terms recur in the conversation about formulation, and at Codeage both are taken seriously. They are not interchangeable, and neither is subordinated to the other. They speak to different stages of the same work.

Bioavailability speaks to the form an ingredient takes — which version, which chelate, which extract, which isomer, which source. It is a question about the ingredient itself: in what state should this compound enter the formulation, and which version of it is most usable. The choice of a chelated rather than a non-chelated mineral, a methyl rather than an unconverted vitamer, a food-derived rather than an isolated extract, is a bioavailability question. Bioavailability informs the work of compound selection — the decisions made before an ingredient enters a composition.

Absorption speaks to something adjacent but distinct: the body's capability to take in what has been given to it — the process by which a formulation, once consumed, encounters the systems that act on it. It is a question about the meeting between formulation and body: in what delivery format does the composition arrive, and how does that format relate to the body's encounter with what it carries. Absorption informs the work of form choice — capsule, powder, liposomal delivery, chewable, tablet, liquid — once the composition has been settled.

Both questions belong to formulation. The bioavailability question is asked when the ingredients themselves are being chosen — which version of which compound enters the work. The absorption question is asked once the composition is settled — in what physical state the composition reaches the reader. Both questions are taken with care; neither is treated as ornament; neither stands above the other.

This page is concerned primarily with absorption, because the choice of form — capsule, powder, liposomal, and so on — is most directly an absorption question. The choice of which form of which ingredient is more directly a bioavailability question, articulated elsewhere in the practice and particularly in the work of compound selection collected across The Compounds Library.

The choice to use liposomal delivery in a particular formulation, for instance, is shaped by the absorption question — how the body tends to encounter certain ingredients once they have entered the system. Where an ingredient is taken in without further assistance, liposomal delivery is not required. Where the question of taking-in is more open, liposomal delivery is one of several approaches considered. For the specific practice and the principles that govern its use at Codeage, see Helix Liposomal Delivery. For the vocabulary that informs both questions, see The Longevity Glossary.

No claim is made, on this page or anywhere else, about the bioavailability or absorption outcome of any particular formulation. The discussion here describes how the conversation is held within the practice — not how it is resolved for any specific composition.

The work begins with the composition. The ingredients are determined, the proportions are settled, the purpose of the formulation is named. The question that follows is: in what form does this composition best reach the reader?

Several considerations enter at once. The character of the ingredients themselves — their chemistry, their behaviour in different physical states, their stability over time. The question of how the body tends to encounter each ingredient, and whether the formulation as a whole would benefit from an assisted delivery format such as Helix Liposomal Delivery. The dose required per serving — whether it fits comfortably in capsule form or calls for the carrying capacity of a powder. The reader who will take the formulation — whether the chewable form suits the demographic, whether the powder suits the routine, whether the simplest capsule suits the moment. And the manufacturing process — whether the chosen form can be produced reliably, batch after batch, at the standard the practice requires.

Each consideration applies pressure on the others. The form that emerges is the one in which the most considerations align — not perfectly, but coherently. Where two considerations conflict, the formulation work mediates between them. Where they cannot be reconciled, the composition itself is revisited. The form, like the composition, is held in a state of considered iteration.

For the broader discipline this sits within, see How the Work Is Made. For the elements before they are formed, see The Compounds Library.